Effect of corticosteroids on hemostasis and pulmonary arterial pressure during chronic obstructive pulmonary disease exacerbation

Respiration

Volumn 75, Issue 2, 2008, Pages 145-154

  Kunter, Erdogan ^a,b   Ilvan, Ahmet ^a   Ozmen, Namik ^a   Demirer, Ersin ^a   Ozturk, Ahmet ^a   Avsar, Kadir ^a   Sayan, Ozkan ^a   Kartaloǧlu, Zafer ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Chronic obstructive pulmonary disease; Corticosteroids; Hemodynamics; Hemostasis

Indexed keywords

ACETYLCYSTEINE; ANTITHROMBIN III; CLARITHROMYCIN; CORTICOSTEROID; D DIMER; FIBRINOGEN; IPRATROPIUM BROMIDE; METHYLPREDNISOLONE; PADGEM PROTEIN; PROTEIN C; PROTEIN S; SALBUTAMOL;

ADULT; AGED; ARTICLE; BLOOD GAS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMODYNAMICS; HEMOSTASIS; HUMAN; LUNG ARTERY PRESSURE; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SPIROMETRY; THROMBOCYTE AGGREGATION;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; BLOOD GAS ANALYSIS; BLOOD PRESSURE; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PULMONARY ARTERY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY;

EID: 40549118169     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097748     Document Type: Article

References (41)

1. Hurd S: The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000;117:1s-4s.
2. Onder I, Topcu S, Dokmetas HS, Turkay C, Seyfikli Z: Platelet aggregation size and volume in chronic obstructive pulmonary disease. Mater Med Pol 1997;29:11-13.
3. Ashitani J, Mukae H, Arimura Y, Matsukura S: Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med 2002;41:181-185.
4. Rostagno C, Prisco D, Boddi M, Poggesi L: Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Eur Respir J 1991;4: 147-151.
5. Erelel M, Cuhadaroglu C, Ece T, Arseven O: The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2002;96:515-518.
6. Hartmann IJC, Hagen PJ, Melissant CF, Postmus PE, Prins MH, on behalf of the Antelope Study Group: Diagnosing acute pulmonary embolism. Am J Respir Crit Care Med 2000;162:2232-2237.
7. Gottschalk A, Stein PD, Henry JV: Patient stratification by cardiopulmonary status in the diagnosis of pulmonary embolism. J Nucl Med 1996;37:570-572.
8. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
9. Cheitlin MD, Armstrong WF, Aurigemma GP, et al: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 2003;42:954-970.
10. Confalonieri M, Gazzaniga PC, Della Porta R, Gandola L, Aiolfi S, Frisinghelli A, Bellone A: Haemodynamic response during initiation of noninvasive positive pressure ventilation in COPD patients with acute ventilatory failure. Respir Med 1998;92:331-337.
11. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, et al: Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-194.
12. Camilli AE, Robbins DR, Lebowitz MD: Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991;133:795-800.
13. Zielinski J, MacNee W, Wedzicha J, Ambrosino N, Braghiroli A, Dolensky J, et al: Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997;52:43-47.
14. Goldhaber SZ, Simons GR, Elliot CG, et al: Quantitative plasma D-dimer levels among patients undergoing pulmonary angiography for suspected pulmonary embolism. JAMA 1993;270:2819.
15. Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Cordova C: Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic obstructive bronchitis and haemostasis group. Thromb Haemost 1994;72:343-346.
16. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW: Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-215.
17. Park CS, Chung SW, Ki SY, Lim GI, Uh ST, Kim YH, Choi DI, Pa JS, Lee DW, Kitaichi M: Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. Am J Respir Crit Care Med 2000;162:1162-1168.
18. Martin LD, Rochelle LG, Fischer BM, Krunkovsky TM, Adler KB: Airway epithelium as an effector of inflammation: molecular regulation of secondary mediators. Eur Respir J 1997;10:2139-2146.
19. Gobay C, Kushner I: Acute phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
20. Rothwell M, Rampling MW, Cholerton S, Sever PS: Haemorheological changes in the short term after abstention from tobacco by cigarette smokers. Br J Haematol 1991;79: 500-503.
21. Morten D, Anne TH, Jorgen V, Peter L, Borge GN: Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1008-1011.
22. Mennen LI, Balkau B, Charles MA, D'Hour A, le Mauff JM: Gender differences in the relation between fibrinogen, tissue-type plasminogen activator antigen and markers of insulin resistance: effects of smoking. DESIR Study Group. Thromb Haemost 1999;82:1106-1111.
23. Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Murohara T, Imaizumi T: Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol 2005;45:1280-1286.
24. Tailor A, Cooper D, Granger DN: Platelet-vessel wall interactions in the microcirculation. Microcirculation 2005;12:275-285.
25. Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY: Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med 2005;37:61-66.
26. Cella G, Sbarai A, Mazzaro G, Vanzo B, Romano S, Hoppensteadt T, Fareed J: Plasma markers of endothelial dysfunction in chronic obstructive pulmonary disease. Clin Appl Thromb Hemost 2001;7:205-208.
27. Ferroni P, Basili S, Martini F, Vieri M, Labbadia G, Cordova C, Alessandri C, Gazzaniga PP, Basil S: Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. J Investig Med 2000;48:211-217.
28. Nenci GG, Berrettini M, Todisco T, Costantini V, Parise P: Effects of dipyridamole on the hypoxemic pulmonary hypertension of patients with chronic obstructive pulmonary disease. Respiration 1988;53:13-19.
29. Ashitani J, Mukae H, Arimura Y, Matsukura S: Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med 2002;41:181-185.
30. Kaminskaia GO, Serebrianaia BA, Kazakova LV: Status of the hemostatic system in patients with chronic lung diseases. Probl Tuberk 1991;8:5-8.
31. Angelov A, Zekov C: Thrombotic complications originating in the lung in chronic respiratory insufficiency. Z Erkr Atmungsorgane 1984;162:256-261.
32. Gazzaniga PP, Basili S, Ferroni P, Pulcinelli FM, Pettirossi G, La Mancusa R, Alessandri C, Cordova C: Chronic obstructive pulmonary disease. A possible correlation between platelet aggregation tests and respiratory indexes. ECOB Group. Clin Ter 1993;142:507-516.
33. Rostagno C, Prisco D, Boddi M, Poggesi L: Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Eur Respir J 1991;4: 147-151.
34. Pandit HB, Spillert CR: Effect of methylprednisolone on coagulation. J Natl Med Assoc 1999;91:453-456.
35. Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM: Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 2000;23:145-150.
36. Sin DD, Man SF: Why are patients with COPD at increased risk of cardiovascular disease? The potential role of systemic inflammation in COPD. Circulation 2003;107: 1514-1519.
37. Gan WQ, Man SF, Senthilselvan A, Sin DD: The association between COPD and systemic inflammation: a systematic review and a metaanlysis. Thorax 2004;59:574-580.
38. Sin D, Lacy P, York E, Man SFP: Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:760-765.
39. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC: The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165: 1592-1596.
40. Confalonieri M, Mainardi E, Della Porta R, Bernorio S, Gandola L, Beghe B, Spanevello A: Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583-585.
41. Davies L, Angus RM, Calverley PM: Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999;354: 456-460.